Zenas BioPharma, Inc. (ZBIO) stock
ZBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$27.75−0.18 (-0.64%)
Close on Nov 17, 2026Market cap $1.81BP/E –Yield –
Zenas BioPharma r&d expenses
Research and development expenses are spending on new products and technology.
Zenas BioPharma's R&D Expenses for the twelve months ending Sep 30, 2026 was $237.55M, up 47.1% year over year. For fiscal 2025 it was $168.06M, up 20.8% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $168.06M | +20.8% |
| FY2024 | Dec 31, 2024 | $139.14M | +131.8% |
| FY2023 | Dec 31, 2023 | $60.03M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $58.47M | +70.0% |
| Q2 FY2026 | Jun 30, 2026 | $62.91M | +46.2% |
| Q1 FY2026 | Mar 31, 2026 | $60.44M | +73.1% |
| Q4 FY2025 | Dec 31, 2025 | $55.72M | +13.4% |
| Q3 FY2025 | Sep 30, 2025 | $34.40M | +2.6% |
| Q2 FY2025 | Jun 30, 2025 | $43.03M | +27.3% |
| Q1 FY2025 | Mar 31, 2025 | $34.92M | +54.2% |
| Q4 FY2024 | Dec 31, 2024 | $49.16M | +140.8% |
| Q3 FY2024 | Sep 30, 2024 | $33.53M | +258.5% |
| Q2 FY2024 | Jun 30, 2024 | $33.81M | – |
| Q1 FY2024 | Mar 31, 2024 | $22.65M | – |
| Q4 FY2023 | Dec 31, 2023 | $20.42M | – |
| Q3 FY2023 | Sep 30, 2023 | $9.35M | – |
See a number that looks wrong?